Telix Pharmaceuticals (TLX) Invested Capital (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Invested Capital data on file, last reported at $405.0 million in Q4 2025.

• Invested Capital for Q4 2025 came in at $405.0 million, down 45.63% year-over-year; the trailing twelve-month figure through Dec 2024 was $744.9 million (up 587.81% YoY), and the FY2025 annual result was $405.0 million, down 45.63% from the prior year.
• Invested Capital slipped to $405.0 million in Q4 2025 per TLX's latest filing, from $744.9 million in the prior quarter.
• Over five years, Invested Capital peaked at $744.9 million in Q4 2024 and troughed at $108.3 million in Q4 2023.
• A 3-year average of $419.4 million and a median of $405.0 million in 2025 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2024 and 2025: Invested Capital soared 587.81% in 2024, then plunged 45.63% in 2025.
• A 3-year view of Invested Capital shows it stood at $108.3 million in 2023, then soared by 587.81% to $744.9 million in 2024, then sank by 45.63% to $405.0 million in 2025.
• Business Quant data shows TLX's Invested Capital at $405.0 million in Q4 2025, $744.9 million in Q4 2024, and $108.3 million in Q4 2023.